Nothing said here yet.
to join the conversation.
| TWOMEY CHRISTOPHER JDirector | Sell | 1,700 | $32.6K | Tue, Oct 27 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Sep 29 | Fri, Oct 9 |
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care shares have climbed back from a deep multi year slump, which puts a fresh spotlight on what investors are paying for each dollar of the company’s sales today.
LONDON, Oct. 19, 2026 /PRNewswire/ -- The global perovskite solar cell market was valued at USD 58.2 million in 2025 and is projected to reach USD 1.73 billion by 2035, according to Credence Research.
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes.
Andrew Schwartz and Bhavik Patel reunite after xtraCHEF to build an AI platform designed specifically for restaurant operators PHILADELPHIA, Sept.
Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit.
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.